Beeline Medicines Announces Presentation of Phase 2 Results of Afimetoran in Systemic Lupus Erythematosus at ACR Convergence 2026
All three afimetoran doses met the primary endpoint with a placebo-adjusted difference in SRI-4 re
All three afimetoran doses met the primary endpoint with a placebo-adjusted difference in SRI-4 re